Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 1/20 | 0.81 |
| ▸ | IDE | P14735 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17592960 | 0.87 | LMNA (0.69) | PHGDHIDEKDM4EPOLBMEN1 | |
| SCHEMBL17593234 | 0.87 | IDE (0.67) | PHGDHIDEKDM4EPOLBTP53 | |
| SCHEMBL17593329 | 0.85 | IDE (0.68) | PHGDHIDEKDM4EPOLBTP53 | |
| SCHEMBL17593188 | 0.84 | IDE (0.69) | PHGDHIDEKDM4EPOLBTP53 | |
| SCHEMBL17593316 | 0.83 | IDE (0.67) | PHGDHIDEKDM4EPOLBMEN1 | |
| SCHEMBL17593266 | 0.82 | IDE (0.60) | PHGDHIDEKDM4EPOLBTP53 | |
| SCHEMBL17593212 | 0.81 | PHGDH (0.66) | PHGDHIDEKDM4ETP53MEN1 | |
| SCHEMBL17593045 | 0.80 | IDE (1.00) | PHGDHIDEKDM4EPOLBMEN1 | |
| SCHEMBL17593090 | 0.80 | ALDH1A1 (0.62) | PHGDHKDM4EPOLBTP53MEN1 | |
| SCHEMBL27716724 | 0.79 | ACR (0.70) | PHGDHKDM4EPOLBTP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220400732-A1 | ANTI-FRUCTOSE THERAPY FOR COLORECTAL AND SMALL INTESTINE CANCERS | CORNELL UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| WO-2016040449-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220400732-A1 | ANTI-FRUCTOSE THERAPY FOR COLORECTAL AND SMALL INTESTINE CANCERS | KHK, GCK, FN3K | PHGDH 275/4885IDE 792/4885KDM4E 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.